Serena Barachini

1 Introduction Over the past two decades, the introduction of immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 antibodies (Abs), used in triplet or quadruplet regimens, has markedly improved MM outcomes, raising the 5-year survival rate from 32% to 58% [1]. However, most patients eventually relapse and MM remains incurable, highlighting the need for new therapies for those refractory to triple- or penta-drug regimens.

1 Introduction Thymic epithelial tumors (TETs) are rare neoplasms of the anterior mediastinum [1]. TETs are classified into thymic carcinomas and thymomas, which are further subdivided into histotypes A, AB, B1, B2, and B3. Mixed histotypes, including B1–B2 and B2–B3, are common, and the 2021 WHO classification has introduced the concepts of metaplastic thymoma and micronodular thymoma with lymphoid stroma [1].

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.